Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Catalyst Health Ventures (CHV) is a venture capital firm based in Boston, Massachusetts, established to invest in transformative medical technology (MedTech) solutions that address global unmet healthcare needs. Founded by Darshana Zaveri and Joshua S. Phillips, CHV focuses on supporting innovative healthcare solutions through close collaboration with entrepreneurs. The firm provides essential resources, mentorship, and connections to help navigate the complexities of the healthcare landscape.
Currently, CHV operates with a team of five professionals, including partners and analysts, and has a strong focus on early-stage investments. The firm primarily targets companies in the seed through Series B stages, particularly during critical transitions from pre-clinical to clinical development. CHV's portfolio includes several notable companies that have been acquired by leading firms in the MedTech sector, showcasing its successful investment strategy.
CHV's notable milestones include the successful exits of portfolio companies such as Veracyte, Inc. and Boston Scientific. The firm is committed to identifying and supporting high-value medical devices that can significantly impact healthcare outcomes.
CHV invests in early-stage companies that are developing breakthrough medical technologies, including therapeutic devices, digital health solutions, and diagnostic devices. The firm typically engages with companies at the seed through Series B stages, particularly during transitions from pre-clinical to clinical development. CHV emphasizes capital efficiency, strong technological foundations, clear regulatory pathways, and scalable business models.
The firm is agnostic to specific therapeutic areas but shows a particular interest in high-value medical devices that can significantly impact healthcare. CHV seeks to partner with entrepreneurs who demonstrate a clear vision and the ability to navigate the complexities of the healthcare market. Their investment strategy is designed to support businesses that not only have innovative technologies but also possess the potential for substantial market impact.
CHV's portfolio includes several notable companies that have achieved significant milestones in the MedTech sector. The following companies are part of their investment history:
These companies have been acquired by leading firms in the MedTech sector, highlighting CHV's successful investment strategy and its focus on high-impact medical technologies.
Darshana Zaveri - Founder & Managing Partner. Darshana has extensive experience in venture capital and healthcare investments, focusing on MedTech innovations.
Joshua S. Phillips - Founder & Managing Partner. Joshua brings a wealth of knowledge in early-stage investments and has a strong background in healthcare technology.
David Mackey - Partner & Chief Financial Officer. David oversees financial operations and has a deep understanding of the MedTech market.
Mimi Dunn - Senior Investment Analyst. Mimi supports the investment team with market analysis and due diligence on potential portfolio companies.
Joshua Lang, MD - Venture Advisor. Joshua provides clinical insights and guidance on medical technologies, enhancing CHV's investment strategy.
Neil Rens, MD, MBA, MSc - Venture Fellow. Neil contributes his expertise in healthcare and business to support portfolio companies.
To pitch to CHV, founders should use the contact email info@chv.vc or visit their investor portal at https://chv.vc. A comprehensive pitch deck should be included, detailing the business model, technology, and market potential. CHV appreciates clear and concise presentations that highlight the startup's unique value proposition.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, but cold outreach is also accepted.
In recent months, CHV has been active in promoting its portfolio and team developments. Notable blog posts include the commercial launch of Instylla's Embrace™ Hydrogel Embolic System, which represents a significant advancement in medical technology.
Additionally, CHV announced the promotion of David Mackey to Partner, reflecting the firm's commitment to internal growth and development. Furthermore, a collaboration between Abbott and AtaCor Medical on advanced ICD technology was highlighted, showcasing CHV's engagement with industry advancements.
What are CHV's investment criteria?
CHV invests in early-stage companies developing breakthrough medical technologies, particularly those in the seed through Series B stages. They look for businesses with strong technological foundations, clear regulatory pathways, and scalable business models.
How can I apply or pitch to CHV?
Founders can pitch to CHV by visiting their website and using the contact email provided. A detailed pitch deck should be included, outlining the business model, technology, and market potential.
What makes CHV different from other venture capital firms?
CHV focuses specifically on the MedTech sector and emphasizes collaboration with entrepreneurs. They provide not only capital but also mentorship and resources to help navigate the complexities of healthcare.
What is CHV's geographic scope?
CHV primarily invests in North America, targeting innovative healthcare startups that address unmet medical needs.
What is the typical check size for investments?
While specific check sizes are not disclosed, CHV typically invests in early-stage rounds, which can range from seed funding to Series B investments.
What is CHV's post-investment involvement like?
CHV actively engages with portfolio companies, providing mentorship, resources, and connections to help them succeed in the healthcare market.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.